Novel MLL/KMT2A‐MON2 fusion in a child with therapy‐related acute myeloid leukemia after treatment for acute promyelocytic leukemia. Issue 11 (8th July 2021)

• Record Type: Journal Article
• Authors: Gong, Yanlei; Wang, Man; Shen, Hongjie; Chen, Yan; Cen, Jiannong; Yin, Xiaolin; Yao, Li
• Is Part Of: Molecular carcinogenesis. Volume 60:Issue 11(2021)
• Page Start: 721
• Page End: 725
• Publication Date: 2021-07-08
• Subjects: acute promyelocytic leukemia -- MLL/KMT2A -- MON2 -- therapy‐related acute myeloid leukemia; Carcinogenesis -- Molecular aspects -- Periodicals; 616.994071
• DOI: 10.1002/mc.23333
• Languages: English
• ISSNs: 0899-1987

Abstract

Abstract: Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML), which is characterized by the reciprocal t (15;17) (q24; q21) translocation, resulting in PML–RARA gene fusion. Therapy‐related AML (t‐AML) is a serious complication after cytotoxic and/or radiation therapy in many malignant diseases. In this report, MLL/KMT2A‐MON2, with balanced chromosomal translocation t (11;12) (q23; q14), was identified as a novel fusion in a child transformed to t‐AML after successful treatment of APL. This study emphasized that clinical monitoring with an integrated laboratory approach is essential for the diagnosis and treatment of t‐AML.